Loss of Heterozygosity at the BRCA1 and BRCA2 Loci Detected in Ductal Lavage Fluid from BRCA Gene Mutation Carriers and Controls

Female BRCA gene mutation carriers are at increased risk for developing breast cancer. Ductal lavage is a novel method for sampling breast ductal fluid, providing epithelial cells for cytologic assessment and a source of free DNA for molecular analyses. Loss of heterozygosity (LOH) at the BRCA loci in ductal lavage fluid is a potential biomarker of breast cancer risk. The LOH rate was measured at the BRCA1/2 loci and compared with that at a control locus (APC) using free DNA from the ductal lavage fluid of BRCA carriers and predictive test negative controls. We evaluated the reproducibility of these analyses. Free DNA sufficient for PCR amplification was obtained from 33 ductal lavage samples of 17 healthy women of known BRCA status (14 BRCA carriers and 3 controls). LOH rates of 36.4% to 56.3% at the BRCA1 locus and 45% to 61.5% at the BRCA2 locus were found among BRCA carriers. The LOH rate at the APC locus was lower (18.5%). The interaliquot reproducibility for the D17S855 marker of the BRCA1 locus was 66.7%. Intraaliquot reproducibility was 90%. Although we successfully isolated sufficient free DNA from ductal lavage fluid for PCR amplification, the degree of reproducibility of these LOH studies raises questions about the robustness of this technique as a risk assessment tool in the evaluation of high-risk women. Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development. (Cancer Epidemiol Biomarkers Prev 2006;15(7):1399–402)

[1]  Minetta C. Liu,et al.  Detection of LOH and Mitochondrial DNA Alterations in Ductal Lavage and Nipple Aspirate Fluids from High-risk Patients , 2004, Breast Cancer Research and Treatment.

[2]  F. Wright,et al.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. , 2003, American journal of human genetics.

[3]  J. Benítez,et al.  Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer , 2002, International journal of cancer.

[4]  Rochelle L. Garcia,et al.  Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. , 2005, American journal of obstetrics and gynecology.

[5]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[6]  R. Dahse,et al.  Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Emily White,et al.  Factors contributing to mammography failure in women aged 40-49 years. , 2004, Journal of the National Cancer Institute.

[8]  I. Campbell,et al.  Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale , 2006, Cancer Epidemiology Biomarkers & Prevention.

[9]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[10]  C. Powell,et al.  Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  B. Ljung,et al.  Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. , 2001, Journal of the National Cancer Institute.

[12]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[13]  D. Bishop,et al.  The Adenomatous Polyposis Coli (APC) gene microsatellite marker D5S1385 is equally informative for loss of heterozygosity as the marker D5S346. , 2003, Experimental and molecular pathology.